Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: Rationale and design of a randomized controlled trial

Contemporary Clinical Trials

Volumn 32, Issue 5, 2011, Pages 704-709

  Kilbreath, Sharon ^a   Refshauge, Kathryn M ^a   Beith, Jane ^b   Ward, Leigh ^c   Sawkins, Kate ^a   Paterson, Ross ^a   Clifton Bligh, Philip ^d   Sambrook, Philip N ^d   Simpson, Judy M ^e   Nery, Liza ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aromatase inhibitors; Breast cancer; Exercise; Osteoporosis

Indexed keywords

AROMATASE INHIBITOR; CALCIUM CARBONATE; VITAMIN D;

ADULT; ARTICLE; AUSTRALIA; BLOOD SAMPLING; BONE DENSITY; BONE MINERAL; BREAST CANCER; CLINICAL PROTOCOL; CLINICAL RESEARCH; DIET SUPPLEMENTATION; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY CANCER; EXERCISE; FEMALE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT OUTCOME;

ABSORPTIOMETRY, PHOTON; AROMATASE INHIBITORS; BONE DENSITY; BREAST NEOPLASMS; EXERCISE THERAPY; FEMALE; HUMANS; OSTEOPOROSIS; POSTMENOPAUSE; PROGNOSIS; RESEARCH DESIGN; RISK FACTORS; SINGLE-BLIND METHOD; VITAMIN D; WOMEN'S HEALTH;

EID: 79960890947     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2011.04.012     Document Type: Article

References (53)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Altundag K., Ibrahim N.K. Aromatase inhibitors in breast cancer: an overview. Oncologist 2006, 11:553-562.
3. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
4. Jahanzeb M. Reducing the risk for breast cancer after completion of tamoxifen treatment in postmenopausal women. Clin Ther 2007, 29:1535-1547.
5. Cella D., Fallowfield L.J., Cella D., Fallowfield L.J. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008, 107:167-180.
6. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
7. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
8. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
9. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.[see comment]. Lancet 2005, 366:455-462.
10. Jakesz R., Greil R., Gnant M., et al. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 2007, 99:1845-1853.
11. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005, 23:5138-5147.
12. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006, 42:1044-1051.
13. Perez E., Josse R., Pritchard K., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635.
14. Goss P.E., Ingle J.N., Martino S., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271.
15. Lonning P., Geisler J., Krag L., et al. Effects of exemestane administered for 2years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005, 23:5126-5137.
16. Harper-Wynne C., Ross G., Sacks N., et al. Effects of aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002, 11:614-621.
17. Cella D., Fallowfield L. Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapy. Breast Cancer Res Treat 2008, 107:167-180.
18. Bonaiuti D., Shea B., Iovine R., et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2002, CD000333.
19. Wallace B.A., Cumming R.G. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women. Calcif Tissue Int 2000, 67:10-18.
20. Engelke K., Kemmler W., Lauber D., Beeskow C., Pintag R., Kalender W.A. Exercise maintains bone density at spine and hip EFOPS: a 3-year longitudinal study in early postmenopausal women. Osteoporos Int 2006, 17:133-142.
21. O'Neil S., MacLennan A., Bass S., et al. Guidelines for the management of postmenopausal osteoporosis for GPs. Aust Fam Physician 2004, 33:910-919.
22. Peppone L.J., Mustian K.M., Janelsins M.C., et al. Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. Clin Breast Cancer 2010, 10:224-229.
23. Moher D., Schulz K.F., Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol 2001, 1:2.
24. CRAIG C.L., MARSHALL A.L., SJÃ-STRÃ-M M., et al. International physical activity questionnaire: 12-Country reliability and validity. Med Sci Sports Exerc 2003, 35:1381-1395.
25. Oken M., Creech R., Tormey D., Horton J. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
26. Hillner B., Ingle J., Chlebowski R., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
27. Hadji P., Body J.J., Aapro M.S., et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008, 19:1407-1416.
28. Lester J.E., Dodwell D., Horsman J.M., Mori S., Coleman R.E. Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom. Br J Cancer 2006, 94:30.
29. Fiatarone Singh M. Exercise and fracture prevention: a guide for consumers 2007, Osteoporosis, Australia. O. Australia (Ed.).
30. Bravo G., Gauthier P., Roy P.M., et al. Impact of a 12-month exercise program on the physical and psychological health of osteopenic women. J Am Geriatr Soc 1996, 44:756-762.
31. Grove K.A., Londeree B.R. Bone density in postmenopausal women: high impact vs low impact exercise. Med Sci Sports Exerc 1992, 24:1190-1194.
32. Cheng S., Sipila S., Taaffe D.R., Puolakka J., Suominen H. Change in bone mass distribution induced by hormone replacement therapy and high-impact physical exercise in post-menopausal women. Bone 2002, 31:126-135.
33. Chow R., Harrison J.E., Notarius C. Effect of two randomised exercise programmes on bone mass of healthy postmenopausal women. Br Med J Clin Res Ed 1987, 295:1441-1444.
34. Kemmler W., Engelke K., Weineck J., Hensen J., Kalender W.A. The Erlangen Fitness Osteoporosis Prevention Study: a controlled exercise trial in early postmenopausal women with low bone density-first-year results. Arch Phys Med Rehabil 2003, 84:673-682.
35. Milliken L.A., Going S.B., Houtkooper L.B., et al. Effects of exercise training on bone remodeling, insulin-like growth factors, and bone mineral density in postmenopausal women with and without hormone replacement therapy. Calcif Tissue Int 2003, 72:478-484.
36. Nelson M.E., Fiatarone M.A., Morganti C.M., Trice I., Greenberg R.A., Evans W.J. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures randomized controlled trial. Jama 1994, 272:1909-1914.
37. Maddalozzo G.F., Widrick J.J., Cardinal B.J., Winters-Stone K.M., Hoffman M.A., Snow C.M. The effects of hormone replacement therapy and resistance training on spine bone mineral density in early postmenopausal women. Bone 2007, 40:1244-1251.
38. Cussler E.C., Lohman T.G., Going S.B., et al. Weight lifted in strength training predicts bone change in postmenopausal women. Med Sci Sports Exerc 2003, 35:10-17.
39. Noble B.J., Borg G.A., Jacobs I., Ceci R., Kaiser P. A category-ratio perceived exertion scale: relationship to blood and muscle lactates and heart rate. Med Sci Sports Exerc 1983, 15:523-528.
40. Teixeira P.J., Going S.B., Houtkooper L.B., et al. Resistance training in postmenopausal women with and without hormone therapy. Med Sci Sports Exerc 2003, 35:555-562.
41. von Stengel S., Kemmler W., Kalender W.A., Engelke K., Lauber D. Differential effects of strength versus power training on bone mineral density in postmenopausal women: a 2-year longitudinal study. Br J Sports Med 2007, 41:649-655. discussion 55.
42. Stengel S.V., Kemmler W., Pintag R., et al. Power training is more effective than strength training for maintaining bone mineral density in postmenopausal women. J Appl Physiol 2005, 99:181-188.
43. Arthritis and osteoporosis in Australia 2008. Arthritis series no 8 2008, AIHW: Australian Institute of Health and Welfare, Canberra.
44. O'Neill S., MacLennan A., Bass S., et al. Guidelines for the management of postmenopausal osteoporosis for GPs. Aust Fam Physician 2004, 33:910-919.
45. Sprangers M.A., Groenvold M., Arraras J.I., Franklin J., te Velde A., Muller M., et al. The European organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996, 14:2756-2768.
46. Hjermstad M.J., Fossa S.D., Bjordal K., Kaasa S. Test/retest study of the European organization for research and treatment of cancer core quality-of-life questionnaire. J Clin Oncol 1995, 13:1249-1254.
47. Aaronson N., Ahmedzai S., Bergman B., et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
48. McHorney C.A., Ware J.E., Lu J.F., Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994, 32:40-66.
49. Cornish B.H., Chapman M., Hirst C., et al. Early diagnosis of lymphedema using multiple frequency bioimpedance. Lymphology 2001, 34:2-11.
50. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215-1223.
51. Dupont W.D., Plummer W.D. Power and sample size calculations. A review and computer program. Control Clin Trials 1990, 11:116-128.
52. Dupont W.D., Plummer W.D. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998, 19:589-601.
53. Registries) AAIoHaWAAAoC Cancer in Australia: an overview. AIHW 2006, 2007.